Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation
Status:
RECRUITING
Trial end date:
2031-11-01
Target enrollment:
Participant gender:
Summary
This study will compare post-transplant health-related quality of life following the use of standard versus attenuated dose of post-transplant cyclophosphamide in addition to two-drug graft-versus-host disease (GVHD) prophylaxis among recipients of allogeneic hematopoietic stem cell transplant.